Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 404950-80-7 Chemical Structure| 404950-80-7

Structure of Panobinostat
CAS No.: 404950-80-7

Chemical Structure| 404950-80-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor with antineoplastic activities. It induces HIV-1 virus production at low concentrations (8-31 nM) and stimulates HIV-1 expression in latently infected cells. Panobinostat also induces cell apoptosis and autophagy and can be used for studying refractory or relapsed multiple myeloma.

Synonyms: LBH589; NVP-LBH589

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Panobinostat

CAS No. :404950-80-7
Formula : C21H23N3O2
M.W : 349.43
SMILES Code : O=C(NO)/C=C/C1=CC=C(CNCCC2=C(C)NC3=C2C=CC=C3)C=C1
Synonyms :
LBH589; NVP-LBH589
MDL No. :MFCD09833242
InChI Key :FPOHNWQLNRZRFC-ZHACJKMWSA-N
Pubchem ID :6918837

Safety of Panobinostat

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301+H331-H315-H318-H360-H373
Precautionary Statements:P201-P202-P260-P264-P270-P271-P280-P301+P310+P330-P302+P352-P304+P340+P311-P305+P351+P338+P310-P308+P313-P332+P313-P403+P233-P405-P501
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Panobinostat

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC

    HDAC (MOLT-4 cells), IC50:5 nM

    HDAC (Reh cells), IC50:20 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
U23674 cells 45 nM 72 h Panobinostat did not consistently diminish PAX3:FOXO1 at either the mRNA or protein level in murine aRMS cells PMC6432638
Rh41 cells 45 nM 24 h Panobinostat did not consistently diminish PAX3:FOXO1 at either the mRNA or protein level in human aRMS cells PMC6432638
SJG 2 0.033 μM 72 h Panobinostat inhibited SJG 2 cell proliferation with an IC50 value of 0.033 μM. PMC7335346
U87 0.105 μM 72 h Panobinostat inhibited U87 cell proliferation with an IC50 value of 0.105 μM. PMC7335346
Rh30 cells 45 nM 24 h Panobinostat did not consistently diminish PAX3:FOXO1 at either the mRNA or protein level in human aRMS cells PMC6432638
BHP 2-7 cells 0.05 μM 48 h Panobinostat alone increased iodine-metabolizing gene expression, promoted radioiodine uptake and toxicity, and suppressed GLUT1 expression in all the cells. PMC6389779
K1 cells 0.05 μM 48 h Panobinostat alone increased iodine-metabolizing gene expression, promoted radioiodine uptake and toxicity, and suppressed GLUT1 expression in all the cells. PMC6389779
BCPAP cells 0.05 μM 48 h Panobinostat alone increased iodine-metabolizing gene expression, promoted radioiodine uptake and toxicity, and suppressed GLUT1 expression in all the cells. PMC6389779
ID8-luc cells 25 nM 24 h Panobinostat in combination with olaparib decreased cell viability, reduced HR repair efficiency, and enhanced DNA damage. PMC8702851
SKOV-3 cells 25 nM 8 h Panobinostat in combination with olaparib significantly downregulated the expression of 20/37 HR pathway genes and significantly enriched immune and inflammatory-related pathways. PMC8702851
SAOS2-LM7 1.8, 2.4, 3.3, 4.5, 6.0, 8.1, 11.0, 14.8, 20 nM 24 h To evaluate the cytotoxicity of panobinostat on osteosarcoma cell lines, results showed that panobinostat exhibited significant cytotoxicity at low concentrations. PMC7787271
SAOS2 1.8, 2.4, 3.3, 4.5, 6.0, 8.1, 11.0, 14.8, 20 nM 24 h To evaluate the cytotoxicity of panobinostat on osteosarcoma cell lines, results showed that panobinostat exhibited significant cytotoxicity at low concentrations. PMC7787271
K7M2 1.8, 2.4, 3.3, 4.5, 6.0, 8.1, 11.0, 14.8, 20 nM 24 h To evaluate the cytotoxicity of panobinostat on osteosarcoma cell lines, results showed that panobinostat exhibited significant cytotoxicity at low concentrations. PMC7787271
SK-N-AS cells 10 nM 48 h Combined with THZ1, significantly reduced the expression of JMJD6, N-Myc, c-Myc, and E2F2 PMC6658504
CHP134 cells 10 nM 48 h Combined with THZ1, significantly reduced the expression of JMJD6, N-Myc, c-Myc, and E2F2 PMC6658504

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice ID8-luc ovarian cancer model Intraperitoneal (IP) 2.5 mg/kg 5 times weekly for 4 weeks Panobinostat in combination with olaparib significantly reduced tumor burden and proliferation, increased tumor apoptosis and DNA damage, enhanced infiltration of CD8+ T cells into tumors, and decreased expression of M2-like macrophage markers. PMC8702851
Mice K7M2 osteosarcoma model Intraperitoneal injection 10 mg/kg 5 days on, 2 days off To evaluate the inhibitory effect of panobinostat on osteosarcoma growth and metastasis, results showed that panobinostat significantly inhibited primary osteosarcoma growth and lung metastasis, and extended the survival of mice. PMC7787271
NOD/SCID mice AML xenograft model Intraperitoneal injection 5 mg/kg Twice per week for 3 weeks Combined treatment with SP2509 and PS significantly improved the survival of mice engrafted with AML xenografts without exhibiting any toxicity. PMC4739780
Nude mice SK-N-AS xenograft model Intraperitoneal injection 7.5 mg/kg Once every three days for 21 days Combined with THZ1, synergistically reduced JMJD6 and E2F2 expression, suppressed tumor progression, and led to tumor regression PMC6658504
Mice HCC mouse models Intraperitoneal injection 5mg/kg and 10mg/kg Every other day, continuous treatment Evaluate the therapeutic effect of Panobinostat on HCC PMC11492314

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02506959 Plasma Cell Leukemia ... More >> Plasmacytoma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Less << Phase 2 Recruiting September 14, 2019 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Yago L. Nieto    713-792-8750    ynieto@mdanderson.org    Principal Investigator: Yago L. Nieto Less <<
NCT00449761 Leukemia, Myeloid, Chronic PHASE2 TERMINATED 2008-08-26 City of Hope National Medical ... More >>Center, Duarte, California, 91010, United States|University of Colorado Health Sciences Center/Anschutz Cancer Pavilion, Aurora, Colorado, 80010, United States|Rocky Mountain Cancer Center, Denver, Colorado, 80218, United States|Northwestern University Clinical Research Office, Chicago, Illinois, 60611, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University Chicago Hospital, Chicago, Illinois, 60637, United States|Indiana Blood and Marrow Institute/St. Francis Hospital, Beech Grove, Indiana, 46107, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, 55905, United States|Hackensack University Medical Center/Oncology Research Dept., Hackensack, New Jersey, 07601, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|Duke University Hospital, Durham, North Carolina, 27710, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Emory University School of Medicine-Winship Cancer Institute, Nashville, Tennessee, 37212, United States|Vanderbilt University Medical Center, Clinical Trials Center, Nashville, Tennessee, 37212, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Novartis Investigative Site, Cologne, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Munich, Germany Less <<
NCT01055483 Acute Myeloid Leukemia Phase 1 Completed - France ... More >> Novartis Investigative Site Paris Cedex 4, France, 75181 Novartis Investigative Site Paris, France, 75475 Germany Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Ulm, Germany, 89081 Less <<
NCT00936611 Waldenstrom's Macroglobulinemi... More >>a Less << PHASE2 COMPLETED 2025-11-12 Rocky Mountain Cancer Centers,... More >> Denver, Colorado, 80220, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT00880269 Refractory Leukemia ... More >> Acute Myelogenous Leukemia Less << Phase 2 Completed - -
NCT02802163 Multiple Myeloma Phase 1 Phase 2 Withdrawn(study drug unavailab... More >>le) Less << December 2020 -
NCT00493766 Hormone Refractory Prostate Ca... More >>ncer Less << PHASE1 TERMINATED - Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115-6-84, United States|Washing University School of Medicine, Saint Louis, Missouri, 63110, United States|Nevada Cancer Institute, Las Vegas, Nevada, 89135, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|Duke University Medical Center, Durham, North Carolina, 27705, United States Less <<
NCT02145715 Multiple Myeloma Phase 1 Phase 2 Unknown January 2016 United Kingdom ... More >> Birmingham Heartlands Hospital Birmingham, UK, United Kingdom, B9 5SS Royal Liverpool University Hospital Liverpool, United Kingdom, L7 8XP St Bartholomew's Hospital London, United Kingdom, EC1A 7BE University College London Hospitals NHS Foundation Trust London, United Kingdom, WC1E 6AG Guy's Hospital London, United Kingdom Less <<
NCT00880269 - Completed - -
NCT00918333 Adult Nasal Type Extranodal NK... More >>/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma B-cell Adult Acute Lymphoblastic Leukemia Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Hepatosplenic T-cell Lymphoma Nodal Marginal Zone B-cell Lymphoma Post-transplant Lymphoproliferative Disorder Primary Central Nervous System Non-Hodgkin Lymphoma Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Hodgkin Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Multiple Myeloma Splenic Marginal Zone Lymphoma T-cell Adult Acute Lymphoblastic Leukemia Waldenstr?m Macroglobulinemia Less << Phase 1 Phase 2 Active, not recruiting December 2018 United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Maryland Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States, 20892 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT00918333 - Active, not recruiting - -
NCT00738751 Lung Cancer H... More >>ead and Neck Cancer Less << Phase 1 Completed - United States, Florida ... More >> H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 Less <<
NCT01111526 Graft-Versus-Host Disease Phase 1 Phase 2 Completed - United States, Florida ... More >> H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT00878436 Prostate Cancer ... More >> Prostatic Neoplasms Less << Phase 1 Phase 2 Completed - United States, New Jersey ... More >> The Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, New York North Shore University Hospital-Monter Cancer Center Lake Success, New York, United States, 11042 NYU Cancer Center New York, New York, United States, 10016 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 Less <<
NCT01111526 - Completed - -
NCT00777335 Breast Cancer Phase 2 Terminated(Very low recruiteme... More >>nt rate.) Less << - United States, California ... More >> UCLA Los Angeles, California, United States, 90095-1678 Less <<
NCT01055795 Advanced Solid Tumors Phase 1 Completed - United States, North Carolina ... More >> Duke University Medical Center Durham, North Carolina, United States, 27710 Less <<
NCT00873002 Liver Cancer Phase 1 Terminated(Dose Limiting Toxic... More >>ity) Less << - United States, Ohio ... More >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less <<
NCT02204553 Multiple Myeloma NO_LONGER_AVAILABLE - Ironwood Cancer and Research C... More >>enters Ironwood Cancer, Chandler, Arizona, 85224, United States|Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, 72703, United States|Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C, Anaheim, California, 92807, United States|Alta Bates Cancer Center, Berkeley, California, 94704, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, 90017, United States|Stanford Cancer Center Stanford Cancer Institute (2), Stanford, California, 94305, United States|George Washington U Medical Center Medical Faculty Associates, Washington, District of Columbia, 20037, United States|University Cancer Institute Univ. Cancer Institute, Boyton Beach, Florida, 33426, United States|Memorial Cancer Institute Memorial Cancer Inst., Hollywod, Florida, 33021, United States|Lakes Research SC, Miami Lakes, Florida, 33014, United States|Emory University School of Medicine/Winship Cancer Institute Winship Cancer Institute (2), Atlanta, Georgia, 30322, United States|Stormont-Vail Cancer Center, Topeka, Kansas, 66606, United States|Hematology Oncology Clinic Hematology Oncology Clinic, Baton Rouge, Louisiana, 70808, United States|Sinai Hospital of Baltimore Sinai Hospital, Baltimore, Baltimore, Maryland, 21215, United States|Bronson Battle Creek Cancer Care Center, Battle Creek, Michigan, 49017, United States|University of Mississippi Medical Center Cancer Institute, Jackson, Mississippi, 39216-9941, United States|Research Medical Center Research Med. Center, Kansas City, Missouri, 64132, United States|Oncology Hematology West, PC Nebraska Cancer Specialists, Omaha, Nebraska, 68124, United States|Hematology Oncology of Central New Jersey, Little Silver, New Jersey, 07739, United States|Morton Coleman, MD M. Coleman, MD (2), New York, New York, 10021, United States|Cancer Centers of the Carolinas GHS Cancer Institute, Greenville, South Carolina, 29615, United States|Wellmont Medical Associates, Bristol, Tennessee, 37620, United States|Texas Oncology Texas Oncology - Arlington, Dallas, Texas, 75251, United States|Texas Oncology TX Oncology Baylor, Dallas, Texas, 75251, United States|Northern Utah Cancer Associates SC, Ogden, Utah, 84403-3105, United States|Virginia Oncology Associates Virginia Oncology Assoc. (2), Norfolk, Virginia, 23502, United States|Fox Valley Hematology and Oncology, Appleton, Wisconsin, 54915, United States Less <<
NCT01090973 Non-Hodgkin's Lymphoma PHASE2 TERMINATED 2025-03-11 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<
NCT00878436 - Completed - -
NCT01090973 Non-Hodgkin's Lymphoma PHASE2 TERMINATED 2025-03-11 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<
NCT00788931 HER-2 Positive Breast Cancer ... More >> Metastatic Breast Cancer Less << Phase 1 Completed - United States, Alabama ... More >> Novartis Investigative Site Mobile, Alabama, United States, 36688 Australia, South Australia Novartis Investigative Site Woodville, South Australia, Australia, 5011 Belgium Novartis Investigative Site Bruxelles, Belgium, 1000 Novartis Investigative Site Liege, Belgium, 4000 Italy Novartis Investigative Site Macerata, MC, Italy, 62100 Novartis Investigative Site Aviano, PN, Italy, 33081 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1066 CX Less <<
NCT00859222 - Completed - -
NCT01169636 Hodgkin's Lymphoma Phase 1 Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01083602 Relapsed and Bortezomib Refrac... More >>tory Multiple Myeloma Refractory Multiple Myeloma Multiple Myeloma in Relapse Less << Phase 2 Completed - United States, California ... More >> University of California at Los Angeles Los Angeles, California, United States, 90095 Stanford University Medical Center Division of Hematology Stanford, California, United States, 94305-5826 United States, Florida H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst. Atlanta, Georgia, United States, 30322 Georgia Regents University MedCollege of GA Cancer Ctr 2 Augusta, Georgia, United States, 30912 United States, Illinois Hematology/Oncology of the North Shore Orchard Healthcare Res. Inc. Skokie, Illinois, United States, 60076 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New Jersey Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2) Somerset, New Jersey, United States, 08873 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 United States, North Carolina Duke University Medical Center Dept. of DUMC (4) Durham, North Carolina, United States, 27710 United States, Tennessee Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt UMC Nashville, Tennessee, United States, 37212 United States, Texas MD Anderson Cancer Center/University of Texas MD Anderson CC Houston, Texas, United States, 77030 United States, Wisconsin Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT00859222 Malignant Glioma Phase 1 Phase 2 Completed - United States, Illinois ... More >> Northwestern University Chicago, Illinois, United States, 60611 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth-Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Virginia University of Virginia, Department of Neurology Charlottesville, Virginia, United States, 22908 Less <<
NCT01083602 - Completed - -
NCT00532389 Multiple Myeloma PHASE1 COMPLETED 2025-10-13 Innovative Medical Research of... More >> South Florida Dept.ofInnovativeMedResearch, Miami Shores, Florida, 33138, United States|Dana Farber Cancer Institute Clinical Research Coordinator, Boston, Massachusetts, 02115, United States|Hackensack University Medical Center Multiple Myeloma Division, Hackensack, New Jersey, 07601, United States|Swedish Medical Center Dept.ofSwedishMedicalCtr., Seattle, Washington, United States|Novartis Investigative Site, Canberra, Australian Capital Territory, 2606, Australia|Novartis Investigative Site, Vancouver, British Columbia, V5Z 1M9, Canada|Novartis Investigative Site, Montreal, Quebec, H1T 2M4, Canada|Novartis Investigative Site, Berlin, 10117, Germany|Novartis Investigative Site, Kiel, 24105, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, München, 80336, Germany|Novartis Investigative Site, Wuerzburg, 97070, Germany|Novartis Investigative Site, Bologna, BO, 40138, Italy|Novartis Investigative Site, Torino, TO, 10126, Italy|Novartis Investigative Site, Salamanca, Castilla Y Leon, 37007, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain Less <<
NCT00777335 - Terminated(Very low recruiteme... More >>nt rate.) Less << - -
NCT02676323 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndrome Less << Phase 1 Terminated(Slow accrual) - United States, California ... More >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States, 94304 Rady Children's Hospital and Health Center San Diego, California, United States, 92123 United States, Michigan Children's Hospital of Michigan Detroit, Michigan, United States, 48201 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas Cook Children's Medical Center Fort Worth, Texas, United States, 76104 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Less <<
NCT01005797 Renal Cancer ... More >>Non Small Cell Lung Cancer (NSCLC) Soft Tissue Sarcoma Less << Phase 1 Completed - United States, South Carolina ... More >> Medical University of South Carolina Hollings Cancer Center Charleston, South Carolina, United States, 29425 Less <<
NCT02057640 Multiple Myeloma ... More >> Kahler Disease Plasma-Cell Myeloma Myelomatosis Less << Phase 1 Phase 2 Active, not recruiting December 2018 United States, Ohio ... More >> University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less <<
NCT00686218 Leukemia Phase 1 Completed - United States, California ... More >> City of Hope Medical Center Duarte, California, United States, 91010-3000 South Pasadena Cancer Center South Pasadena, California, United States, 91030 United States, Washington Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Less <<
NCT00445068 Multiple Myeloma PHASE2 TERMINATED 2009-12-25 Mayo Clinic, Scottsdale, Arizo... More >>na, 85259, United States|Aptium Oncology, Berkeley, California, 94704, United States|City of Hope, Duarte, California, 91010, United States|UCSF, San Francisco, California, 94143, United States|Stanford, Stanford, California, 94305, United States|Rocky Mountain Cancer Center, Denver, Colorado, 80218, United States|Christiana Care, Newark, Delaware, 19718, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Emory University, Atlanta, Georgia, 30322, United States|Rush University, Chicago, Illinois, 60612, United States|University of Chicago, Chicago, Illinois, 60637, United States|Indiana University, Indianapolis, Indiana, 46203, United States|University of Iowa, Iowa City, Iowa, 52240-1515, United States|Dana Farber, Boston, Massachusetts, 02115, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Washington University, Saint Louis, Missouri, 63110, United States|Hackensack University, Hackensack, New Jersey, 07456, United States|Duke, Durham, North Carolina, 27710, United States|Wake Forest, Winston-Salem, North Carolina, 27157, United States|Metrohealth, Cleveland, Ohio, 44109, United States|Sarah Canon Research Center, Nashville, Tennessee, 37203, United States|Vanderbilt, Nashville, Tennessee, 37212, United States|University of Texas Southwestern, Dallas, Texas, 75390-9179, United States|CTRC, San Antonio, Texas, 78258, United States|Novartis investigative Site, Berlin, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Starnberg, Germany|Novartis Investigative Site, Wuerzburg, Germany Less <<
NCT02290431 Relapse/Refractory Multiple My... More >>eloma Less << Phase 2 Recruiting July 8, 2019 Japan ... More >> Nagoya City University Hospital Recruiting Nagoya City, Aichi, Japan, 467-8602 Novartis Investigative Site Completed Kashiwa-city, Chiba, Japan, 277-8567 Matsuyama Red Cross Hospital Recruiting Matsuyama-City, Ehime, Japan, 790-8524 Novartis Investigative Site Terminated Fukuoka city, Fukuoka, Japan, 812-8582 Novartis Investigative Site Recruiting Ogaki-city, Gifu, Japan, 503-8502 Gunma University Hospital Recruiting Maebashi-city, Gunma, Japan, 371-8511 Principal Investigator: Hiroshi Handa, M.D.          Novartis Investigative Site Recruiting Shibukawa-city, Gunma, Japan, 377-0280 Novartis Investigative Site Completed Kure-city, Hiroshima, Japan, 737-0023 Kobe City Medical Center General Hospital Recruiting Kobe, Hyogo, Japan, 650-0047 Mito Medical Center Recruiting Higashiibaraki-gun, Ibaraki, Japan, 311-3193 University Hospital, Kyoto Prefectural, University of Medicine Recruiting Kamigyo-ku, Kyoto, Japan, 602-8566 Novartis Investigative Site Recruiting Sendai-shi, Miyagi, Japan, 983 8520 Niigatq Cancer Ce3nter Hospital Recruiting Kawagishi-cho, Chuo-ku, Niigata, Japan, 951-8566 Novartis Investigative Site Completed Okayama-city, Okayama, Japan, 701-1192 Osaka University Hospital Recruiting Yamadaoka, Suita-City, Osaka, Japan, 565-0871 Novartis Investigative Site Completed Utsunomiya-shi, Tochigi, Japan, 320-0834 Tokushima University Hospital Recruiting Tokushima-City, Tokushima, Japan, 770-8503 Novartis Investigative Site Completed Koto-ku, Tokyo, Japan, 135 8550 Japanese Red Cross Medical Center Recruiting Shibuya-Ku, Tokyo, Japan, 150-8935 Center Hospital of the National Center for Global Health and Medicine Recruiting Shinjuku-ku, Tokyo, Japan, 162-8655 Principal Investigator: Akiyoshi Miwa, M.D.          Novartis Investigative Site Recruiting Tachikawa, Tokyo, Japan, 190-0014 Novartis Investigative Site Recruiting Aomori, Japan, 030 8553 Less <<
NCT01324635 Recurrent Glioma ... More >> High-grade Meningioma Brain Metastasis Less << Phase 1 Terminated(Arm A - reached goa... More >>l; Arm B - poor accrual) Less << - United States, Pennsylvania ... More >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT03256045 Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less << Phase 2 Recruiting May 16, 2024 United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker    206-606-7273    pbecker@u.washington.edu    Principal Investigator: Pamela S. Becker Less <<
NCT01034657 - Terminated(The study was termi... More >>nated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties.) Less << - -
NCT00667862 Prostate Cancer PHASE2 COMPLETED 2010-11-05 University of Maryland, Baltim... More >>ore, Maryland, 21201, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States|Washington University, Saint Louis, Missouri, 63130, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University of Wisconsin, Madison, Wisconsin, 53706-1481, United States Less <<
NCT01034657 Myelodysplastic Syndrome (MDS) Phase 2 Terminated(The study was termi... More >>nated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties.) Less << - Germany ... More >> Novartis Investigative Site Mannheim, Baden-Württemberg, Germany, 68305 Novartis Investigative Site Berlin, Germany, 12203 Novartis Investigative Site Bonn, Germany, 53105 Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Duesseldorf, Germany, 40225 Novartis Investigative Site Duisburg, Germany, 47166 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Goettingen, Germany, 37075 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site Muenchen, Germany, 81675 Novartis Investigative Site Ulm, Germany, 89081 Less <<
NCT02756663 Multiple Myeloma Phase 2 Withdrawn February 2021 -
NCT01159418 Advanced Solid Tumors Phase 1 Unknown March 2012 Switzerland ... More >> Huniversitätsspitals Basel Basel, Switzerland, 4031 Istituto Oncologico della Svizzera Italiana Bellinzona, Switzerland, 6500 Mèdecin Adjoint, ME - CePO, CHUV Lausanne, Switzerland, 1011 Less <<
NCT00472368 Cancer Patients With Advanced ... More >>Solid Tumors Including Lymphoma or Chronic Hematological Malignancies Less << PHASE1 COMPLETED - Novartis Investigative Site, B... More >>uffalo, New York, 14263, United States Less <<
NCT00490776 Cutaneous T-Cell Lymphoma PHASE2 TERMINATED 2009-09-22 University of Alabama at Birmi... More >>ngham/ The Kirklin Clinic, Birmingham, Alabama, 35233, United States|UCLA Medical Center School of Medicine/ Dpt of Hematology-Oncology, Los Angeles, California, 90095, United States|University of Colorado Health Sciences Center/Anschutz Cancer Pavillion, Aurora, Colorado, 80010, United States|Florida Academic Dermatology Centers, Miami, Florida, 33136, United States|Medical College of Georgia, Augusta, Georgia, 30912, United States|Rush Presbyterian Hospital/St. Luke's Medical Center, Chicago, Illinois, 60612, United States|St. Louis University Cancer Cennter, Saint Louis, Missouri, 63110, United States|Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Our Lady of Mercy Medical Center/Comprehensive Cancer Center, Bronx, New York, 10466, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|NYU Clinical Cancer Center, New York, New York, 10016, United States|Wake University Health Sciences, Winston-Salem, North Carolina, 27157, United States|University of Oklahoma-Tulsa, Tulsa, Oklahoma, 74104, United States|Craig Okada, Portland, Oregon, 97239, United States|University of Pittsburg Medical Center, Pittsburgh, Pennsylvania, 15213, United States|The Jones Clinic, Germantown, Tennessee, 38138, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, 77030, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109-102, United States Less <<
NCT01238692 Diffuse Large B Cell Lymphoma Phase 2 Unknown December 2016 Canada, Nova Scotia ... More >> Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada, H3T 1E2 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Sacré-Cœur Hospital Montreal, Quebec, Canada, H4J 1C5 Less <<
NCT02588339 Graft Versus Host Disease ... More >> GVHD Less << Phase 2 Active, not recruiting December 2020 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT01056601 - Terminated(Funding not availab... More >>le) Less << - -
NCT01056601 Pancreatic Cancer Phase 2 Terminated(Funding not availab... More >>le) Less << - United States, Minnesota ... More >> Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States, 55455 Less <<
NCT01032148 Hodgkin's Lymphoma|Non-Hodgkin... More >>'s Lymphoma Less << PHASE1 TERMINATED 2025-01-17 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263, United States Less <<
NCT02720510 - Terminated(A study was termina... More >>ted due to low enrollment.) Less << - -
NCT00412997 Tumors|Cutaneous T-Cell Lympho... More >>ma Less << PHASE1 COMPLETED - Novartis Investigative Site, T... More >>okyo, Japan Less <<
NCT02720510 Multiple Myeloma Phase 2 Terminated(A study was termina... More >>ted due to low enrollment.) Less << - United States, California ... More >> David Geffen School of Medicine at UCLA UCLA Los Angeles, California, United States, 90095 United States, Florida Memorial West Cancer Center Memorial Cancer Institute Pembroke Pines, Florida, United States, 33028 United States, Georgia Northside Hospital Central Research Dept. Atlanta, Georgia, United States, 30342 United States, Nebraska Oncology Hematology West Nebraska Cancer Specialists dbaNebraska Cancer Specialists Omaha, Nebraska, United States, 68124 United States, Texas Brooke Army Medical Center Hematology/Oncology San Antonio, Texas, United States, 78234 Less <<
NCT01440582 Myeloma Phase 1 Active, not recruiting February 1, 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01034163 - Completed - -
NCT00891033 Multiple Myeloma Phase 1 Terminated(This study was term... More >>inated because the drug company stopped making the study drug) Less << - United States, Arkansas ... More >> Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 Less <<
NCT01007968 Advanced Solid Tumors PHASE1 COMPLETED 2025-11-12 University of Utah / Huntsman ... More >>Cancer Institute, Salt Lake City, Utah, 84103, United States|Novartis Investigative Site, Leiden, 2300 RC, Netherlands|Novartis Investigative Site, Lund, SE-221 85, Sweden|Novartis Investigative Site, Stockholm, SE-171 76, Sweden|Novartis Investigative Site, St. Gallen, 9007, Switzerland|Novartis Investigative Site, Edinburgh, EH4 2XR, United Kingdom Less <<
NCT01965353 Multiple Myeloma in Relapse Phase 1 Active, not recruiting December 2019 United States, Massachusetts ... More >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 Less <<
NCT01034163 Hodgkin's Lymphoma Phase 3 Completed - -
NCT00503451 Non-Hodgkin Lymphoma|Neoplasms PHASE1 COMPLETED - Nevada Cancer Institute, Las V... More >>egas, Nevada, 89135, United States|Novartis Investigative Site, Rotterdam, Netherlands Less <<
NCT00946647 Myelodysplastic Syndromes ... More >> Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia Less << Phase 1 Active, not recruiting June 13, 2019 -
NCT00567879 Breast Cancer Phase 1 Phase 2 Terminated(The study was termi... More >>nated early due to insufficient evidence of clinical benefit.) Less << - United States, California ... More >> University of California at Los Angeles Los Angeles, California, United States, 90095 United States, Colorado University of Colorado Dept. of Univ. of Colorado Aurora, Colorado, United States, 80045 United States, Connecticut Norwalk Hospital Dept of Norwalk Hospital (2) Norwalk, Connecticut, United States, 06856 United States, Maryland VA Maryland Health Care Dept.of GreenbaumCancerCent(3) Baltimore, Maryland, United States, 21201 United States, Missouri The Center for Cancer Care and Research St. Louis, Missouri, United States, 63141 United States, Ohio Ohio State Comprehensive Cancer Center/James Cancer Hospital SC Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital Pittsburgh, Pennsylvania, United States, 15232 Canada, British Columbia Novartis Investigative Site Kelowna, British Columbia, Canada, V1Y 5L3 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H3T 1E2 France Novartis Investigative Site Dijon Cedex, France, 21034 Novartis Investigative Site Paris, France, 75231 Novartis Investigative Site Saint-Herblain Cédex, France, 44805 Germany Novartis Investigative Site Heidelberg, Germany, 69115 Italy Novartis Investigative Site Meldola, FC, Italy, 47014 Novartis Investigative Site Genova, GE, Italy, 16132 Novartis Investigative Site Modena, MO, Italy, 41100 United Kingdom Novartis Investigative Site Birmingham, United Kingdom, B15 2TH Novartis Investigative Site London, United Kingdom, W12 0HS Novartis Investigative Site Manchester, United Kingdom, M20 4BX Less <<
NCT01028313 Chronic Graft-Versus-Host Dise... More >>ase Less << Phase 2 Withdrawn(A decision was made ... More >>to not move forward with the study. No participants were enrolled or treated.) Less << - United States, Tennessee ... More >> Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 Less <<
NCT00632489 - Completed - -
NCT00567879 - Terminated(The study was termi... More >>nated early due to insufficient evidence of clinical benefit.) Less << - -
NCT00777049 Breast Cancer PHASE2 COMPLETED 2025-04-15 UCLA, Los Angeles, California,... More >> 90095-1678, United States Less <<
NCT00777049 Breast Cancer PHASE2 COMPLETED 2025-04-15 UCLA, Los Angeles, California,... More >> 90095-1678, United States Less <<
NCT01463046 Acute Myeloid Leukemia ... More >> Advanced Myelodysplastic Syndrome Less << Phase 1 Active, not recruiting December 2018 United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94143 Less <<
NCT00594230 Myelodysplastic Syndromes (MDS... More >>) Less << PHASE2 TERMINATED 2025-03-11 Florida Cancer Specialists, Fo... More >>rt Myers, Florida, 33901, United States|Northeast Georgia Medical Center, Gainesville, Georgia, 30501, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, 40207, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, 20817, United States|Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37023, United States Less <<
NCT00594230 Myelodysplastic Syndromes (MDS... More >>) Less << PHASE2 TERMINATED 2025-03-11 Florida Cancer Specialists, Fo... More >>rt Myers, Florida, 33901, United States|Northeast Georgia Medical Center, Gainesville, Georgia, 30501, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, 40207, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, 20817, United States|Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37023, United States Less <<
NCT00632489 Breast Cancer Phase 1 Completed - United States, Tennessee ... More >> Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 Less <<
NCT00550277 Renal Cell Carcinoma PHASE2 COMPLETED 2025-06-10 Florida Cancer Specialists, Fo... More >>rt Myers, Florida, 33901, United States|Northeast Georgia Medical Center, Gainesville, Georgia, 30501, United States|Baton Rouge General Medical Center, Baton Rouge, Louisiana, 70806, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, 20817, United States|Methodist Cancer Center, Omaha, Nebraska, 68114, United States|Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, 07960, United States|Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37023, United States|Peninsula Cancer Institute, Newport News, Virginia, 23601, United States Less <<
NCT00570284 Cancer PHASE1 COMPLETED 2025-02-11 Novartis Investigative Site, L... More >>os Angeles, California, United States|Novartis Investigative Site, Norwalk, Connecticut, United States|Novartis Investigative Site, Rockville, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Stokholm, Sweden|Novartis Investigative Site, Zurich, Switzerland Less <<
NCT00550277 Renal Cell Carcinoma PHASE2 COMPLETED 2025-06-10 Florida Cancer Specialists, Fo... More >>rt Myers, Florida, 33901, United States|Northeast Georgia Medical Center, Gainesville, Georgia, 30501, United States|Baton Rouge General Medical Center, Baton Rouge, Louisiana, 70806, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, 20817, United States|Methodist Cancer Center, Omaha, Nebraska, 68114, United States|Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, 07960, United States|Oncology Hematology Care, Cincinnati, Ohio, 45242, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37023, United States|Peninsula Cancer Institute, Newport News, Virginia, 23601, United States Less <<
NCT00739414 Cancer|Advanced Solid Tumor PHASE1 COMPLETED - Novartis Investigational Site,... More >> Aichi prefecture, Japan|Novartis Investigational Site, Hokkaido, Japan|Novartis Investigational Site, Hyogo prefecture, Japan Less <<
NCT00848523 Recurrent Malignant Gliomas PHASE2 TERMINATED 2025-04-09 Long Island Brain Tumor Center... More >> at Neurological Surgery PC / Long Island Neuro-Oncology Associates, Commack, New York, 11725, United States|Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates, Great Neck, New York, 11021, United States Less <<
NCT01301807 Non-Secretory Plasma Cell Myel... More >>oma Plasmacytosis Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Less << Phase 1 Active, not recruiting August 31, 2019 United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01298934 Primary Myelofibrosis|Polycyth... More >>emia Vera, Post-Polycythemic Myelofibrosis Phase|Post-Essential Thrombocythemia Related Myelofibrosis Less << PHASE1|PHASE2 UNKNOWN 2025-07-15 Icahn School of Medicine at Mo... More >>unt Sinai, New York, New York, 10029, United States Less <<
NCT00743288 Multiple Myeloma Phase 1 Phase 2 Completed - United States, California ... More >> Comprehensive Blood and Cancer Center Bakersfield, California, United States, 93309-0633 James R. Berenson MD, Incorporated West Hollywood, California, United States, 90069 United States, Colorado Rocky Mountain Cancer Centers - Denver Midtown Denver, Colorado, United States, 80218 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 Less <<
NCT00997399 Advanced Solid Tumors Phase 1 Completed - United States, Utah ... More >> University of Utah / Huntsman Cancer Institute Salt Lake City, Utah, United States, 84103 Netherlands Novartis Investigative Site Leiden, Netherlands, 2300 RC Novartis Investigative Site Utrecht, Netherlands, 3584CX Switzerland Novartis Investigative Site St. Gallen, Switzerland, 9007 United Kingdom Novartis Investigative Site Merseyside, United Kingdom, L63 4JY Less <<
NCT00840346 Acute Myeloblastic Leukaemia Phase 1 Phase 2 Completed - Spain ... More >> Hospital Clinic y Provincial de Barcelona Barcelona, Spain Hospital Germans Trías i Pujol Barcelona, Spain Hospital Santa Creu y Sant Pau. Barcelona Barcelona, Spain Hospital 12 de Octubre. Madrid Madrid, Spain Hospital Clínico San Carlos. Madrid Madrid, Spain Hospital Ramón y Cajal. Madrid Madrid, Spain Hospital Morales Messeguer. Murcia Murcia, Spain Hospital Univ. La Fe de Valencia Valencia, Spain Hospital Lozano Blesa. Zaragoza Zaragoza, Spain Less <<
NCT01023308 Multiple Myeloma Phase 3 Completed - -
NCT01613976 Myelodysplastic Syndromes (MDS... More >>)|Chronic Myelomonocytic Leukemia (CMML)|Acute Myeloid Leukemia (AML) Less << PHASE1 COMPLETED 2025-05-14 Novartis Investigative Site, N... More >>agoya-city, Aichi, 466-8650, Japan|Novartis Investigative Site, Nagoya, Aichi, 460-0001, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0017, Japan|Novartis Investigative Site, Sendai-city, Miyagi, 980-8574, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, 104-0045, Japan|Novartis Investigative Site, Kyoto, 602-8566, Japan Less <<
NCT01023308 - Completed - -
NCT01433445 Idiopathic Myelofibrosis ... More >> Post Essential Thrombocythemia Myelofibrosis Post Polycythemia-Vera Myelofibrosis Less << Phase 1 Active, not recruiting December 31, 2018 France ... More >> Novartis Investigative Site Paris, France, 75010 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Magdeburg, Germany, 39120 Novartis Investigative Site Mainz, Germany, 55131 Ireland Novartis Investigative Site Dublin, Ireland, DUBLIN 8 Novartis Investigative Site Galway, Ireland Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Reggio Calabria, RC, Italy, 89124 Novartis Investigative Site Varese, VA, Italy, 21100 United Kingdom Novartis Investigative Site London, United Kingdom, SE1 9RT Less <<
NCT01013597 Thyroid Carcinoma PHASE2 COMPLETED 2025-02-16 St. Vincent Regional Cancer Ce... More >>nter CCOP, Green Bay, Wisconsin, 54301, United States|University of Wisconsin - Madison, Madison, Wisconsin, 53792, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<
NCT00663832 Prostate Cancer Phase 1 Completed - United States, Maryland ... More >> Novartis Investigative Site Rockville, Maryland, United States, 20850 United States, Michigan Novartis Investigative Site Detroit, Michigan, United States, 48201 United States, Missouri Novartis Investigative Site St. Louis, Missouri, United States, 63110 United States, Nevada Novartis Investigative Site Las Vegas, Nevada, United States, 89135 United States, New York Novartis Investigative Site New York, New York, United States, 10021 United States, North Carolina Novartis Investigative Site Durham, North Carolina, United States, 27710 United States, Oregon Novartis Investigative Site Portland, Oregon, United States, 97239 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1L8 Canada, Ontario Novartis Investigative Site Hamilton, Ontario, Canada, L8V 5C2 Less <<
NCT00670553 Prostate Cancer ... More >> Head & Neck Cancer Esophageal Cancer Less << Phase 1 Completed - Belgium ... More >> Novartis Investigative Site Liege, Belgium Less <<
NCT00743288 - Completed - -
NCT01651039 Multiple Myeloma Phase 2 Completed - United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less <<
NCT01013597 Thyroid Carcinoma PHASE2 COMPLETED 2025-02-16 St. Vincent Regional Cancer Ce... More >>nter CCOP, Green Bay, Wisconsin, 54301, United States|University of Wisconsin - Madison, Madison, Wisconsin, 53792, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<
NCT01136499 Soft Tissue Sarcoma Phase 2 Completed - France ... More >> Centre Léon Berard Lyon, France Less <<
NCT01549431 Multiple Myeloma Phase 1 Active, not recruiting December 2018 United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, Georgia Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 Less <<
NCT01523834 Diffuse Large B-cell Lymphoma PHASE2 COMPLETED 2025-04-17 Azienda Ospedaliera SS. Antoni... More >>o e Biagio e C. Arrigo, Alessandria, 15121, Italy|Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola, Bologna, 40138, Italy|Spedali Civili, Brescia, Italy|Ematologia I, A.O.U. San Martino, Genova, 16132, Italy|Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Italy|Divisione di Ematologia Università Avogadro, Novara, Italy|AO Ospedali Riuniti Villa Sofia-Cervello, Palermo, 90146, Italy|A.O. Città della Salute e della Scienza (Ematologia Univ), Torino, Italy|A.O. Città della salute e della scienza (S.C. Ematologia), Torino, Italy|AO Universitaria di Udine, Udine, Italy Less <<
NCT01321346 Lymphoblastic Leukemia, Acute,... More >> Childhood Myelogenous Leukemia, Acute, Childhood Hodgkin's Disease Non-Hodgkin's Lymphoma Less << Phase 1 Completed - -
NCT01651039 - Completed - -
NCT00901147 Peripheral T-cell Lymphoma (No... More >>t Otherwise Specified) Angioimmunoblastic T-cell Lymphoma Extranodal NK/T-cell Lymphoma Nasal Type Enteropathy- Type T-cell Lymphoma Hepatosplenic T-cell Lymphoma Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant Less << Phase 2 Completed - Korea, Republic of ... More >> Samsung Medical Centre Seoul, Korea, Republic of, 135-710 Malaysia Subang Jaya Medical Centre Subang Jaya, Selangor, Malaysia, 47500 Hospital Universiti Kebangsaan Malaysia ( HUKM ) Kuala Lumpur, Malaysia, 56000 Singapore National Cancer Center Singapore, Singapore, 169608 Singapore General Hospital Singapore, Singapore, 169608 Less <<
NCT01658241 Nodal Lymphoma ... More >> Lymphoma With Cutaneous Involvement Lymphoma in Leukemic Phase Marrow Involvement With Lymphoma Multiple Myeloma Less << Phase 2 Active, not recruiting July 2018 Australia, Victoria ... More >> Peter MacCallum Cancer Centre Melbourne, Victoria, Australia, 3002 Less <<
NCT00925132 - Terminated(Change in the numbe... More >>r of approved drugs for metastatic melanoma) Less << - -
NCT02722941 Multiple Myeloma PHASE2 COMPLETED 2021-01-18 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<
NCT00742027 Classical Hodgkin's Lymphoma PHASE2 COMPLETED 2013-08-12 City of Hope National Medical ... More >>Center Dept.ofCityofHopeMedicalCtr(2), Duarte, California, 91010-3000, United States|Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2), Atlanta, Georgia, 30322, United States|Georgia Regents University Cancer Clinical Research Unit, Augusta, Georgia, 30912, United States|Rush University Medical Center Divisionof Hem/Onc Research(2), Chicago, Illinois, 60612, United States|VA Maryland Health Care Dept.of GreenbaumCancerCent(5), Baltimore, Maryland, 21201, United States|Dana Farber Cancer Institute Hematology / Oncology, Boston, Massachusetts, 02115, United States|Karmanos Cancer Institute Div.of Hematology/Oncology, Detroit, Michigan, 48201, United States|Mayo Clinic - Rochester Hematology, Rochester, Minnesota, 55905, United States|University of Pennsylvania Medical Center Dept of UPenn Med Ctr (3), Philadelphia, Pennsylvania, 19104-4283, United States|University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3), Houston, Texas, 77030-4009, United States|The Methodist Hospital Cell & Gene Therapy Clinic, Houston, Texas, 77030, United States|Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5), San Antonio, Texas, 78229, United States|West Virginia University/ Mary Babb Randolph Cancer Center, Morgantown, West Virginia, 26506, United States|Novartis Investigative Site, Herston, Queensland, 4029, Australia|Novartis Investigative Site, Malvern, Victoria, 3144, Australia|Novartis Investigative Site, Bruxelles, 1000, Belgium|Novartis Investigative Site, Charleroi, 6000, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, 21941-913, Brazil|Novartis Investigative Site, Campinas, SP, 13083-970, Brazil|Novartis Investigative Site, S?o Paulo, SP, 01224-000, Brazil|Novartis Investigative Site, S?o Paulo, SP, 05403-000, Brazil|Novartis Investigative Site, Dijon, 21034, France|Novartis Investigative Site, Lille Cedex, 59 037, France|Novartis Investigative Site, Lyon Cedex, 69373, France|Novartis Investigative Site, Marseille, 13273, France|Novartis Investigative Site, Rennes, 35019, France|Novartis Investigative Site, Villejuif Cedex, 94805, France|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, G?ttingen, 37075, Germany|Novartis Investigative Site, K?ln, 50924, Germany|Novartis Investigative Site, Be'er Sheva, 84101, Israel|Novartis Investigative Site, Jerusalem, 91120, Israel|Novartis Investigative Site, Ramat Gan, 52621, Israel|Novartis Investigative Site, Bologna, BO, 40138, Italy|Novartis Investigative Site, Milano, MI, 20162, Italy|Novartis Investigative Site, Rozzano, MI, 20089, Italy|Novartis Investigative Site, Torino, TO, 10126, Italy|Novartis Investigative Site, Udine, UD, 33100, Italy|Novartis Investigative Site, Selangor, 68000, Malaysia|Novartis Investigative Site, Auckland, New Zealand|Novartis Investigative Site, Singapore, 169608, Singapore|Novartis Investigative Site, Barcelona, Catalu?a, 08025, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Withington, Greater Manchester, M20 4BX, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom Less <<
NCT00925132 Metastatic Melanoma Phase 1 Phase 2 Terminated(Change in the numbe... More >>r of approved drugs for metastatic melanoma) Less << - United States, Iowa ... More >> University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 Less <<
NCT03632317 Glioma Diffus... More >>e Intrinsic Pontine Glioma Less << Phase 2 Recruiting September 2025 United States, Michigan ... More >> University of Michigan Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Carl Koschmann, M.D.    734-615-2736    ckoschma@umich.edu    Principal Investigator: Carl Koschmann, MD Less <<
NCT01460940 Adult Lymphocyte Depletion Hod... More >>gkin Lymphoma Adult Lymphocyte Predominant Hodgkin Lymphoma Adult Mixed Cellularity Hodgkin Lymphoma Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma Adult Nodular Sclerosis Hodgkin Lymphoma Recurrent Adult Hodgkin Lymphoma Less << Phase 2 Completed - United States, Missouri ... More >> Washington University Saint Louis, Missouri, United States, 63110 United States, Ohio The Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT01282476 - Terminated(slow accrual) - -
NCT01460940 - Completed - -
NCT01065467 Melanoma|Malignant Melanoma PHASE1 COMPLETED 2017-03-13 Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02215, United States Less <<
NCT01282476 Diffuse Large B Cell Lymphoma Phase 2 Terminated(slow accrual) - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02214 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT00985946 Neuroendocrine Tumors Phase 2 Terminated(Study did not meet ... More >>statistical requirements to continue.) Less << - United States, Wisconsin ... More >> University of Wisconsin, Madison Madison, Wisconsin, United States, 53792 Less <<
NCT00985946 - Terminated(Study did not meet ... More >>statistical requirements to continue.) Less << - -
NCT00967044 - Completed - -
NCT01504776 Mantle Cell Lymphoma Phase 1 Completed - United States, Georgia ... More >> Georgia Regents University Augusta, Georgia, United States, 30912 Less <<
NCT01693601 Myelofibrosis Phase 1 Phase 2 Active, not recruiting February 2019 United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less <<
NCT01336842 Solid Tumors ... More >>Non-Small Cell Lung Cancer (NSCLC) Less << Phase 1 Completed - United States, California ... More >> University of California Davis Cancer Center Sacramento, California, United States, 95817 United States, Michigan Henry Ford Health System Detroit, Michigan, United States, 48202 Less <<
NCT00931762 Primary Myelofibrosis|Post-Pol... More >>ycythemia Vera|Post-Essential Thrombocytopenia Less << PHASE2 TERMINATED 2011-08-29 Mayo Clinic - Scottsdale, Scot... More >>tsdale, Arizona, 85259, United States|City of Hope National Medical Center, Duarte, California, 91010, United States|Stanford Comprehensive Cancer Center, Stanford, California, 94305, United States|Medical College of Georgia, Augusta, Georgia, 30912, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Mayo Clinic - Rochester, Rochester, Minnesota, 55905, United States|New York Presbyterian Hospital - Weill Cornell Medical College, New York, New York, 10021, United States Less <<
NCT01451268 Myelodysplastic Syndrome ... More >> Acute Myeloid Leukemia Less << Phase 1 Phase 2 Active, not recruiting April 2018 Germany ... More >> University Hospital Düsseldorf Düsseldorf, Germany, 40225 University Hospital Essen Essen, Germany, 45147 University Hospital Frankfurt Frankfurt am Main, Germany, 60590 University Hospital Hamburg-Eppendorf Hamburg, Germany, 20246 University Hospital Mainz Mainz, Germany, 55131 University Hospital Marburg Marburg, Germany, 35043 Less <<
NCT02568943 Multiple Myeloma NO_LONGER_AVAILABLE - Novartis Investigative Site, I... More >>nnsbruck, Tyrol, 6020, Austria|Novartis Investigative Site, Linz, A-4010, Austria|Novartis Investigative Site, Rankweil, A-6830, Austria|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, Vienna, A-1090, Austria|Novartis Investigative Site, Wien, 1140, Austria|Novartis Investigative Site, Kitchener, Ontario, N2G 1G3, Canada|Novartis Investigative Site, Montreal, Quebec, H4J 1C5, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, 68305, Germany|Novartis Investigative Site, Bad Saarow, 15526, Germany|Novartis Investigative Site, Bamberg, 96049, Germany|Novartis Investigative Site, Bayreuth, 95445, Germany|Novartis Investigative Site, Bielefeld, 33604, Germany|Novartis Investigative Site, Bonn, 53105, Germany|Novartis Investigative Site, Bremen, 28177, Germany|Novartis Investigative Site, Chemnitz, 09113, Germany|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Greifswald, 17475, Germany|Novartis Investigative Site, Hamburg, 22763, Germany|Novartis Investigative Site, Hannover, 30449, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, Jena, 07740, Germany|Novartis Investigative Site, Karlsruhe, 76133, Germany|Novartis Investigative Site, Kiel, 24105, Germany|Novartis Investigative Site, Magdeburg, 39120, Germany|Novartis Investigative Site, Mainz, 55131, Germany|Novartis Investigative Site, Muenchen, 81737, Germany|Novartis Investigative Site, Mutlangen, 73557, Germany|Novartis Investigative Site, Nuernberg, 90419, Germany|Novartis Investigative Site, Rostock, 18057, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Winnenden, 71364, Germany|Novartis Investigative Site, Wuerzburg, 97080, Germany|Novartis Investigative Site, Amman, 11941, Jordan|Novartis Investigative Site, Oslo, NO-0424, Norway|Novartis Investigative Site, Trondheim, 7006, Norway|Novartis Investigative Site, Linkoping, SE 581 85, Sweden|Novartis Investigative Site, Stockholm, 14186, Sweden|Novartis Investigative Site, Umea, 901 85, Sweden Less <<
NCT01115036 Recurrent Glioblastoma Phase 2 Withdrawn(No subjects were enr... More >>olled on this study, so study was closed and IND withdrawn.) Less << April 2012 United States, North Carolina ... More >> Duke University Medical Center Durham, North Carolina, United States, 27710 Less <<
NCT00967044 Lymphoma Phase 1 Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01680094 HIV Infection PHASE1|PHASE2 COMPLETED 2025-01-14 Department of Infectious Disea... More >>ses, Aarhus University Hospital, Aarhus, 8200, Denmark Less <<
NCT02032810 Melanoma Skin... More >> Cancer Less << Phase 1 Active, not recruiting December 2019 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT01242774 Acute Myeloid Leukemia (AML) PHASE1 COMPLETED 2025-05-14 Stanford University Medical Ce... More >>nter Stanford U, Stanford, California, 94304, United States|Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr, Boston, Massachusetts, 02115, United States|Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital, Columbus, Ohio, 43210, United States|Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston, South Carolina, 29425, United States|Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 3, Nashville, Tennessee, 37212, United States|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Salamanca, Castilla Y Leon, 37007, Spain|Novartis Investigative Site, Barcelona, 08025, Spain Less <<
NCT02717455 Glioma PHASE1 COMPLETED 2024-03-31 Children's Hospital Los Angele... More >>s, Los Angeles, California, 90026, United States|Stanford University and Lucile Packard Children's Hospital, Palo Alto, California, 94304, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|National Cancer Institute, Bethesda, Maryland, 20892, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 15224, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States|Baylor College of Medicine, Houston, Texas, 77030, United States Less <<
NCT01802879 Hematologic Neoplasms PHASE2 COMPLETED 2018-11-19 City of Hope National Medical ... More >>Center Dept.ofCityofHopeMedicalCtr(1), Duarte, California, 91010 3000, United States|Georgia Regents University SC-2, Augusta, Georgia, 30912, United States|Dana Farber Cancer Institute Reg. Ped, Boston, Massachusetts, 02215, United States|University of Utah / Huntsman Cancer Institute SC-2, Salt Lake City, Utah, 84103, United States|Novartis Investigative Site, Jerusalem, 91120, Israel|Novartis Investigative Site, Leiden, 2300 RC, Netherlands|Novartis Investigative Site, Salamanca, Castilla Y Leon, 37007, Spain Less <<
NCT01496118 Multiple Myeloma Phase 1 Phase 2 Active, not recruiting December 2019 United States, Colorado ... More >> Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists South Fort Myers, Florida, United States, 33916 Woodlands Medical Specialists Pensacola, Florida, United States, 32503 Florida Cancer Specialists North Saint Petersburg, Florida, United States, 33705 United States, Indiana Providence Medical Group Terre Haute, Indiana, United States, 47802 RHHP/Hope Cancer Center Terre Haute, Indiana, United States, 47802 United States, Missouri Research Medical Center Kansas City, Missouri, United States, 64132 United States, New Jersey Hematology-Oncology Associates - Northern NJ Morristown, New Jersey, United States, 07962 United States, Ohio Oncology Hematology Care, Inc. Cincinnati, Ohio, United States, 45242 United States, Oklahoma Cancer Centers of Southwest Oklahoma Lawton, Oklahoma, United States, 73505 United States, Tennessee Tennessee Oncology-Chattanooga Chattanooga, Tennessee, United States, 37404 Tennessee Oncology Nashville, Tennessee, United States, 37205 United States, Texas The Center for Cancer and Blood Disorders Fort Worth, Texas, United States, 76104 Less <<
NCT01245179 Sickle Cell Disease Phase 1 Active, not recruiting July 2023 United States, Georgia ... More >> Augusta University Augusta, Georgia, United States, 30912 Less <<
NCT00621244 Lymphoma|Leukemia|Multiple Mye... More >>loma Less << PHASE1|PHASE2 COMPLETED 2009-12-03 Georgia Health Sciences Univer... More >>sity Dept.ofMedicalCollegeOfGeorgia, Augusta, Georgia, 30912, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, 77030, United States|Novartis Investigative Site, Parkville, Victoria, 3002, Australia|Novartis Investigative Site, Prahran, Victoria, 3181, Australia|Novartis Investigative Site, Frankfurt/M, 60590, Germany|Novartis Investigative Site, Mainz, 55131, Germany Less <<
NCT00535951 Carcinoma, Non-Small-Cell Lung... More >>|Mesothelioma Less << PHASE1 COMPLETED - Highlands Oncology Group, Faye... More >>tteville, Arkansas, 72703, United States|Medical College of Georgia, Augusta, Georgia, 30912, United States|RUSH Medical Center, Chicago, Illinois, 60612, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Novartis Investigative Site, Ontario, Canada Less <<
NCT04326764 Acute Myeloid Leukaemia (AML)|... More >>Myelodysplastic Syndromes (MDS) Less << PHASE3 TERMINATED 2023-02-13 Robert Bosch Krankenhaus, Stut... More >>tgart, Baden-Württemberg, 70376, Germany|University Hospital Jena, Jena, Thüringen, 07747, Germany|Universit?tsklinikum Leipzig, Leipzig, Thüringen, 04103, Germany|Klinikum Augsburg, Augsburg, Germany|University Hospital Bonn, Bonn, Germany|Universtity Hospital Dresden, Dresden, 01307, Germany|University Hospital Frankfurt, Frankfurt, Germany|University Hospital Hamburg-Eppendorf, Hamburg, Germany|Otto-von-Guericke University, Magdeburg, 39120, Germany|Universit?tsmedizin Mainz, Mainz, Germany|Klinikum Mannheim, Mannheim, Germany|Philipps-Universit?t Marburg, Marburg, Germany|University Hospital Münster, Münster, Germany|Klinikum Nürnberg Nord, Nürnberg, 90419, Germany|Amsterdam University Medical Center - VUMC, Amsterdam, 1081 HV, Netherlands|University Medical Center Groningen, Groningen, 9713 GZ, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud UMC, Nijmegen, 6500 HB, Netherlands|Erasmus University Medical Center, Rotterdam, 3015, Netherlands Less <<
NCT00939159 Myelodysplastic Syndrome PHASE2 TERMINATED 2025-06-13 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT04897880 Rhabdoid Tumor|Atypical Terato... More >>id/Rhabdoid Tumor|Malignant Rhabdoid Tumor|Recurrent Brain Tumor, Childhood Less << PHASE2 TERMINATED 2024-05-08 The Preston Robert Tisch Brain... More >> Tumor Center, Duke University Medical Center, Durham, North Carolina, 27710, United States|John Hunter Children's Hospital, New Lambton, New South Wales, 2305, Australia|Sydney Children's Hospital, Randwick, New South Wales, 2031, Australia|The Children's Hospital at Westmead, Westmead, New South Wales, 2145, Australia|Women's and Children's Hospital, North Adelaide, South Australia, 5006, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Monash Children's Hospital, Clayton, Victoria, 3168, Australia|The Royal Children's Hospital, Parkville, Victoria, 3052, Australia|Perth Children's Hospital, Nedlands, Western Australia, 6009, Australia|Starship Children's Hospital, Grafton, Auckland, 1023, New Zealand|Christchurch Hospital, Christchurch, 8011, New Zealand Less <<
NCT00690677 Colorectal Cancer PHASE2 COMPLETED 2025-12-11 Swedish Medical Center, Seattl... More >>e, Washington, 98104, United States Less <<
NCT00425555 Cutaneous T-Cell Lymphoma PHASE2 COMPLETED 2025-06-13 University of Alabama at Birmi... More >>ngham/ Kirklin Clinic Kirklin Clinic, Birmingham, Alabama, 35294-0006, United States|City of Hope National Medical Center, Duarte, California, 91010-3000, United States|University of California at Los Angeles Dept. of Hematology-Oncology, Los Angeles, California, 90095, United States|Florida Academic Dermatology Center, Miami, Florida, 33136, United States|Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2), Atlanta, Georgia, 30322, United States|Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia, Augusta, Georgia, 30912, United States|NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept. of NorthwesterUMed, Chicago, Illinois, 60611, United States|Indiana University Dept. of IU Cancer Center, Indianapolis, Indiana, 46202, United States|Boston Medical Center StudyCoordinator:CLBH589B2201, Boston, Massachusetts, 02118, United States|Dana Farber Cancer Institute Deptof DanaFarberCancerInst(3), Boston, Massachusetts, 02215, United States|University of Michigan Health System Michigan HouseClinTrialsOffice, Ann Arbor, Michigan, 48109, United States|Wake Forest University Baptist Medical Center OutpatientCmprehensivCancerCtr, Winston-Salem, North Carolina, 27157, United States|University Dermatology Consultants, Cincinnati, Ohio, 45219, United States|Oregon Health & Science University Dept. of OHSU Cancer Institute, Portland, Oregon, 97239, United States|University of Pittsburgh Medical Center Department of Dermatology, Pittsburgh, Pennsylvania, 15213, United States|MD Anderson Cancer Center/University of Texas StudyCoordinator:CLBH589B2201, Houston, Texas, 77030, United States|Novartis Investigative Site, Caba, Buenos Aires, C1221ADC, Argentina|Novartis Investigative Site, Buenos Aires, C1425AUM, Argentina|Novartis Investigative Site, South Brisbane, Queensland, 4101, Australia|Novartis Investigative Site, Parkville, Victoria, 3050, Australia|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Yvoir, 5530, Belgium|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1E2, Canada|Novartis Investigative Site, Helsinki, 00250 HUS, Finland|Novartis Investigative Site, Lyon, Cedex 02, 69288, France|Novartis Investigative Site, Creteil, 94010, France|Novartis Investigative Site, Paris, 75010, France|Novartis Investigative Site, Berlin, 13353, Germany|Novartis Investigative Site, Minden, 32423, Germany|Novartis Investigative Site, Würzburg, 97080, Germany|Novartis Investigative Site, Budapest, H-1085, Hungary|Novartis Investigative Site, Ancona, AN, 60126, Italy|Novartis Investigative Site, Bologna, BO, 40138, Italy|Novartis Investigative Site, Firenze, FI, 50129, Italy|Novartis Investigative Site, Torino, TO, 10126, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Zürich, 8091, Switzerland Less <<
NCT00419536 Hormone Refractory Prostate Ca... More >>ncer Disease Less << PHASE1 TERMINATED - Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115-6084, United States|Washington University School of Medicine, St. Louis, Missouri, 63119, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10021, United States Less <<
NCT00451035 Chronic Myeloid Leukemia in Ch... More >>ronic Phase Less << PHASE2 TERMINATED 2008-09-30 Novartis Investigative Site, B... More >>ruxelles, Belgium|Novartis Investigative Site, Godinne, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Cologne, Germany|Novartis Investigative Site, Dusseldorf, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Munich, Germany Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.86mL

0.57mL

0.29mL

14.31mL

2.86mL

1.43mL

28.62mL

5.72mL

2.86mL

References

 

Historical Records

Categories